key: cord-0830984-m1cjgtnd
authors: Shi, Danrong; Chen, Keda; Lu, Xiangyun; Cheng, Linfang; Weng, Tianhao; Liu, Fumin; Wu, Nanping; Li, Lanjuan; Yao, Hangping
title: Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro
date: 2022-01-25
journal: Virol Sin
DOI: 10.1016/j.virs.2022.01.031
sha: 8b55e603a94165a38ae99d1e3d350c2d05b1fbe4
doc_id: 830984
cord_uid: m1cjgtnd

nan

Remdesivir has been shown to be effective against SARS-CoV-2 in vitro in previous studies (Choy et al., 2020; 76 Wang M et al., 2020), but ganciclovir was not. Cell Counting Kit-8 assay mixture (15 µL; MedChemExpress, 77 Monmouth Junction, NJ, USA) was added to each well to measure cell proliferation and cytotoxicity. Three 78 hours after incubation, the absorbance value at 450 nm was measured using a microplate reader (BioRad iMark, 79

Hercules, Cal, USA). rHuIFN-α1b and rHuIFN-α2b had no significant toxic effect on Vero cells at detected 80 concentrations (Fig. 1A, 1B) . For remdesivir and ganciclovir, the 50% cytotoxic concentration (CC50) was 282.4 81 μmol/L and >100 μmol/L respectively in Vero cells (Fig. 1C, 1D) . rHuIFN-α1b, rHuIFN-α2b, and ganciclovir 82 also showed no cytotoxicity toward Calu-3 cells, the CC50 of remdesivir in Calu-3 cells was 49.5 μmol/L (Fig.  83 

To test the antiviral effect of IFN on SARS-CoV-2, Vero cells and Calu-3 cells were inoculated on 24-well 85 plates (Greiner Bio-One) at 1×10 5 /mL/well, and incubated with 5% CO2 at 37 °C to the logarithmic growth 86 phase. Then, the cell culture medium was discarded, and the cells were infected with SARS-CoV-2 (hCoV-87 19/Hangzhou/ZJU-05/2020, GISAID, ID: 415709) at a multiplicity of infection of 0.05 (5% CO2, 35 °C). Three 88 hours after infection, the culture medium containing the virus was removed and the cells were washed twice 89 with phosphate-buffered saline (PBS). After that, 1 mL/well of culture medium containing drugs was added to 90 the pre-infected cells, which were incubated at 35 °C (5% CO2) for 48 h. All experiments were conducted in 91 triplicate and performed in an approved biosafety level III laboratory (CNAS BL0022, State Key Laboratory 92 for Diagnosis and Treatment of Infectious Diseases, Zhejiang University). Forty-eight hours after infection, the 93 culture supernatants were collected to determine the median tissue culture infective dose (TCID50) using the 94 standard TCID50 method (Reed and Muench, 1938) and for reverse-transcription quantitative polymerase chain 95 reaction (RT-qPCR) using a One-Step RT-qPCR Kit (Liferiver, Shanghai, China) according to the 96 manufacturer's instructions. Data were analyzed using Prism software (GraphPad Software, San Diego, CA, 97 USA). The inhibition percentage was calculated as: Inhibition%= (1−2 − △△ Ct ) ×100%. Half-maximal effective 98 concentrations (EC50) were calculated using nonlinear regression. 99

The viral titer steadily decreased with increasing rHuIFN-α1b and rHuIFN-α2b concentrations in both Vero 100 and Calu-3 cells (Fig. 1A, 1B and 1E, 1F ). rHuIFN-α1b had a prominent anti-SARS-CoV-2 effect in the tested 101 concentration range (EC50 = 0.12 IU/mL in Vero cells; EC50 = 0.52 IU/mL in Calu-3 cells) (Fig. 1A, 1E) . 102 rHuIFN-α2b also showed an inhibitory effect (EC50 = 0.25 IU/mL in Vero cells; EC50 = 2.48 IU/mL in Calu-3 103 cells) (Fig. 1B, 1F ), but it was not as good as that of rHuIFN-α1b. Remdesivir also showed a good anti-viral 104 effect (EC50 = 0.67 μmol/mL in Vero cells and 0.81 μmol/mL in Calu-3 cells) (Fig. 1C, 1G ). Ganciclovir showed 105

no antiviral activity in the tested concentration range in either cell types (Fig. 1D, 1H ). at 20-25 °C in the dark. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; 2 µmol/L; Abcam). 113

The stained cells were observed by fluorescence microscopy. The proportion of SARS-CoV-2 infected cells 114 decreased with the increasing concentration of rHuIFN-α1b and rHuIFN-α2b in both Vero (Fig. 1I, 1J ) and Calu-115 3 cells ( Supplementary Fig. S1A , S1B), showing a dose-effect correlation. Remdesivir as the effective antiviral 116 drug control, also had prominent effect, but ganciclovir, as the ineffective drug control, did not. 117 TCID50 values were used to further compare the antiviral effect of rHuIFN-α1b and rHuIFN-α2b. The viral 118 titer steadily decreased with increasing rHuIFN-α1b and rHuIFN-α2b concentrations, but rHuIFN-α1b did better 119 in both Vero and Calu-3 cells (Fig, 1K, 1L ). The results for remdesivir and ganciclovir were consistent with RT-120 qPCR ( Fig. 1C, 1D , 1G, 1H) and immunofluorescence ( Supplementary Fig. S2 ). Taken together, these data 121 indicate that rHuIFN-α1b significantly inhibited SAR-CoV-2 proliferation at a low concentration. CC50=282.4 μmol/L, SI= 421.49) which is very close to previous report (Wang M et al., 2020) . In contrary, 148 ganciclovir, which is also a nucleoside analog, has no antiviral activity to SARS-CoV-2 in our study. This may 149 be due to the low strength of non-specific binding of ganciclovir as a nucleoside analog to polymerase, leading 150 to few anti-virus capabilities. Chen, L., Shi, M., Deng, Q., Liu, W., Li, Q., Ye, P., Yu, X., Zhang, B., Xu, Y., Li, X., Yang, Y., Li, M., Yan, Y., 189 Xu, Z., Yu, J., Xiang, L., Tang, X., Wan, G., Cai, Q., Wang, L., Hu, B., Xie, L., Li, G., Xie, L., Liu, X., 190

Liu, C., Li, L., Chen, L., Jiang, X., Huang, Y., Wang, S., Guo, J., Shi, Y., Li, L., Wang, X., Zhao, Z., Li, 191 Y., Liu, Y., Fu, Q., Zeng, Y., Zou, Y., Liu, D., Wan, D., Ai, T., Liu, H., 2020. A multi-center randomized 192 prospective study on the treatment of infant bronchiolitis with interferon alpha1b nebulization. PLoS 

In vitro inhibition of SARS virus replication by human interferons

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by 205

cyclosporin A or interferon-alpha treatment

Inhibition of SARS-CoV-2 by type I and type III interferons

Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant

Gilead's Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized 214

Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans

No Statistically Apparent Difference

Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus 237

Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild 238 to Moderate Coronavirus Disease

Clinical Efficacy of Therapy with Recombinant Human Interferon alpha1b in Hand, Foot, and 242 Mouth Disease with Enterovirus 71 Infection

Early transmissibility assessment of the 245 N501Y mutant strains of SARS-CoV-2 in the United Kingdom

A novel variant of human interferon alpha 1 gene

The Impact of Mutations

SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-258

Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, 279 and interferon beta against MERS-CoV

Type 283 I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Remdesivir 286 and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Escape from neutralizing antibodies by SARS-CoV-2 spike 292 protein variants

Nowcasting and forecasting the potential domestic and international 294 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

SARS-CoV-2 spike-protein 298 D614G mutation increases virion spike density and infectivity

Coronaviruses -drug discovery and 301 therapeutic options